Navigation Links
Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Date:5/12/2008

d bone loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize these compounds. More information is at http://www.velcura.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
2. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
10. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ACG Annual Scientific Conference -, ORLANDO, Fla....(formerly Microbia) today announced presentation o...ing the role that cyclic guanosine,monophosphate (...studies,demonstrate that cGMP inhibits intestinal ...esia and desensitizes colonic afferent nerves in a...
(Date:10/6/2008)...earch at The American College of Nutrition ...Oct. 6 /- New research on the benefit...ted at The American College of,Nutrition (ACN) Ann...s of,Probiotics in Health and Disease." Scientific...utrition discussed the potential uses for,probioti...
(Date:10/6/2008)... 6 /- Genaera,Corporation (...d Phase 1,clinical trial of trodusquemine (MSI-143...t of type 2 diabetes and obesity. MSI-1436 is a no...et that controls the function,of both the leptin a...ase,appetite. In the study, MSI-1436 was found to ...
(Date:10/6/2008)...Scheduled for 9:00 AM ET Today -, SEATTLE, Oct. 6...asdaq:,DNDN) announced today that it has completed...omized, double-blind, placebo-controlled IMPACT,(I..., also known as D9902B),clinical trial designed to...onal active cellular immunotherapy PROVENGE(R) (si...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 2'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 4Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4New genetic variants associated with lipid levels risk for coronary artery disease 1872 1New genetic variants associated with lipid levels risk for coronary artery disease 1872 2New genetic variants associated with lipid levels risk for coronary artery disease 1872 3New genetic variants associated with lipid levels risk for coronary artery disease 1872 4New genetic variants associated with lipid levels risk for coronary artery disease 1872 55 Problems With Feet That Men Shouldnt Walk Away From 9486 1DHS Begins Collecting 10 Fingerprints From International Visitors at Hartsfield Jackson Atlanta International Airport 1869 1DHS Begins Collecting 10 Fingerprints From International Visitors at Hartsfield Jackson Atlanta International Airport 1869 2Statement of Steve Pasierb President and CEO Partnership for a Drug Free America on New SAMHSA Study On Cough Medicine Abuse 9477 1Statement of Steve Pasierb President and CEO Partnership for a Drug Free America on New SAMHSA Study On Cough Medicine Abuse 9477 2Statement of Steve Pasierb President and CEO Partnership for a Drug Free America on New SAMHSA Study On Cough Medicine Abuse 9477 3Statement of Steve Pasierb President and CEO Partnership for a Drug Free America on New SAMHSA Study On Cough Medicine Abuse 9477 4
... Tolerance Support Development,of Omega DUROS Cont...2, 2007 /PRNewswire/ -- Intarcia,Therapeutics, Inc...ay announced final results from a Phase 2 study of...atment-naive patients,with genotype 1 chronic hepa...eron in combination with ribavirin is well tolerat...
...11, 2007 (PRIME NEWSWIRE) --,Hana Biosciences (Nas...advancing cancer care, will present preclinical da...the American Association,for Cancer Research 100th...California. , Abstract No. 2210: "Combining talotr...ll lung cancer (NSCLC) athymic nude,mice xenograft...
Other Medicine Technology:Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting 2Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting 3
(Date:10/6/2008)... special supplement of the Oct. 15,journal Cancer ...,middle-income countries to implement breast cance...ease among women worldwide., "Guidelines for Inte...mentation" developed by the Breast Health Global I...rce allocation -- based on countries,overall econ...
(Date:10/6/2008)...ecently posted detailed information on its Cimzia ...us side effects caused by the drug and its family ...l side effects are the development of fatal infect... child patients. , Denver...ber one resource for everything and anything legal...
(Date:10/6/2008)...-based civil litigation and criminal defense firm ...ury awarded $3.2 million to plaintiff earlier this...land ((Lexis Nexis) October 6, 2008 -- Attorneys i..., Murtha & Psoras] have successfully resolved ...nd welder who was awarded more than $3 million by ...
(Date:10/5/2008)... help detect serious bacterial infections (SBIs) l...ctions in young infants who come to the emergency ...se. Researchers at Children,s Hospital Boston, col... University, show that a new diagnostic marker cal...h risk for SBIs while potentially reducing unneces...
Breaking Medicine News(10 mins):Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:New test could help catch serious infections in babies 2
...ys at a Czech farm where the potentially lethal H5... been slaughtered, officials said on Friday. "All...process is underway for the smaller flocks in the ...all," Czech veterinary services spokesman Zbynek S...
...nned in virtually all public places in Slovenia, a...er 18 banned, under legislation adopted Friday by ...n August, amend for a third time Slovenia's origin...adopted in 1996. Smoking will be banned in all pub...
...nfected almost 20,000 people in Vietnam in the fir...e than in the same period last year, the health mi...alls have been blamed for the nearly 15 percent ri...squito-borne disease, which have been concentrated...
... adults have never had sex in their lives, and the...n-Americans, according to an official survey out o... 20-59 years have had sex, with the age group 20-2...1 percent)," the Center for Disease Control and Pr...
Other Medicine News:
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Medicine Products: